Assessing Cardiac Function of Patients with Chronic Kidney Disease using N-Terminal Pro-brain Natriuretic Peptide Precursor (NT-proBNP)
Abstract
To determine the plasma level of N-terminal brain natriuretic peptide precursor (NT-proBNP） in patients with chronic kidney disease (CKD) and its association with cardiac function. Methods A total of 567 CKD patients admitted to the hospital from January 2013 to December 2014 were divided into six groups according to their estimated glomerular filtration rate. Their plasma level of NT-proBNP, renal function, and cardiac function were determined. Results The worse patients cardiac function，and the lower eGFR，the higher concentration of plasma NT-proBNP. Plasma level of NT-proBNP was negatively correlated with glomerular filtration rate (=－0.529, P<0.01). The receiver operating characteristic curves generated a cutoff NT-proBNP value of 119.5 ng/L, 168.5 ng/L, 300.5 ng/L, 1 019.5 ng/L, 2 777.5 ng/L, and 3 640.5 ng/L, respectively, for diagnosing cardiac failure in the six groups, respectively. Conclusion NT-proBNP is affected by renal function, which can be used for diagnosing cardiac failure in patients with CKD.
Keywords: Chronic kidney disease, N-terminal brain natriuretic peptide precursor, Cardiac function
Full Text:
PDFReferences
National Guideline Clearinghouse ( NGC ). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013, 3 ( 1 ); 1- 150.
LEE SC, STEVENS TL, SANDBERG SM, et al. The potential of brain natriunetic peptide as a biomarker for New York Heart Association class during the outpatient treatment
of heart failure. J Card Fail,2002,8(3); 149-154. MUKOYAMA M.NAKAO K.SALTO Y.elal. Human brain natriuretic peptide,a novel cardiac hormone. Lancet, 1990,335 (8692):801-802.
GUSTAFSSON F, STEENSGA ARD H F, BADSK H AER J , et al. Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure. J Card Fail,2005,11(5): 15-20.
ZAPHIRIOU A, ROBBS S, MURRAY-THOMAS T. et al. The diagnostic accuracy of plasm BNP and NTproBNP in patients referred from primary care with suspected heart faiure: results of the UK natriuretic peptides study. Eur J Heart Fail.2005,7(4) ;537-541.
LAINCHBURY JG, TROUGHTON RW, STRANGMAN KM, et al, N-terminal Pro-B-type natriuretic peptide-guided treatment for chronic heart failure; results from the BATTLESCARRED ( NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmission and death) trial. J Am Coll Cardiol,2009,55( 1); 53-60.
JANUZZI JL, Jr.CAMARGO CA,ANWARUDDIN S, et al. The N-terminal Pro-BNP investigation of dyspnea in Emergency Departmt (PRIDE) study. Am J Cardiol. 2005, 95 (8);948-954.
JANUZZI JL.VAN KIMMENADE R. LAINCHBURY J,et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. Eur Heart J,2006,27(3);330-337.
CORTES R. PORTOLES M. ROSELLO-LLETI E, et al. Impact of glomerular filtration rate on urinary BNP and NT- proBNP levels in heart failure. Peptides, 2012, 33 ( 2 ): 354- 358.
TAKASE H.DOHI Y. Kidney function crucially affects B- type natriuretic peptide ( BNP), N-terminal pro BNP and their relationship. Eur J Clin Invest,2014,44(3) :303-308.
DEFILIPPI C, VAN KIMMENADE RR, PINTO YM. Amino-terminal pro-B-type natriuretic peptide testing in renal disease. Am J Cardiol,2008,101(3):82-88.
HARVEY JM, CLARK GM, OSBORNE C'K. et at. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol, 1999, 17 (5):1474-1481.
YANG Q, OU C LIU M, et al. NR AGE promotes cell proliferation by stabilizing PCNA in a ubiquitin-proteasome pathway in esophageal carcinomas. Carcinogenesis, 2014 , 35 (7):1643-1651.
DU Q, ZHANG Y, TIAN XX, et al. MAGE-D1 inhibits proliferation, migration and invasion of human breast cancer cells. Oncol Rep,2009,22(3) :659-665.
AL-SADI R, KHATIBK, GUOS, elal. Occludin regulates macromolecule flux across the intestinal epithelial tight junction barrier. Am J Physiol Gastr L.2011,300(6) ;C1054- G1064.
MATLUK N, ROCHIRA JA, KARACZYN A, et al. A role for NRAGE in NF-kappaB activation through the non- canonical BMP pathway. BMC Biol,2010,8: 7[2016-10-15]. http://bmcbiol. biomedcentral. com/articles/10. 1186/1741- 7007-8-7. doi: 10. 1186/1741-7007-8-7.
Refbacks
- There are currently no refbacks.
